NCT03050229 - SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study) | Biotech Hunter

Enrollment

174

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

October 31, 2017

Study Completion Date

March 31, 2018

Conditions

Nocturnal HypertensionT2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

Empagliflozin

Empagliflozin 10mg/day once daily before or after breakfast

DRUG

Placebo

Placebo once daily before or after breakfast

Trial Locations (12)

Fukuoka University Chikushi Hospital, Fukuoka

Kotake Hospital, Fukuoka

Onga Hospital, Fukuoka

Ishiguro Clinic, Gifu

Higashiagatsuma-machi National Health Insurance Clinic, Gunma

Katsuya Iin, Hyōgo

Minamisanriku Hospital, Miyagi

Shibuya Clinic, Saitama

International University of Health and Welfare Hospital, Tochigi

Jichi Medical University hospital, Tochigi

Utsunomiya higashi hospital, Tochigi

Kato Clinic, Tokyo